GT Biopharma (GTBP) vs Lisata Therapeutics (LSTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma (GTBP) has outperformed Lisata Therapeutics (LSTA) over the past year, gaining 789.5% versus a loss of 56.4%. Over five years, LSTA leads with a -94.2% price change compared with -96.3% for GTBP. GT Biopharma is the larger company by market cap ($12.1 million vs $11.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GTBP | LSTA |
|---|---|---|
| Share price | $6.68 | $1.06 |
| Market cap | $12.05M | $11.45M |
| 1-day change | +12.27% | -11.67% |
| YTD return | +750.96% | -43.01% |
| 1-year return | +789.48% | -56.38% |
| 5-year return | -96.32% | -94.21% |
| EPS (TTM) | $-161.13 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.75 | $5.07 |
| 52-week low | $4.91 | $0.99 |
| Distance from 52-week high | -76.77% | -79.09% |
| Analyst consensus | none | none |
| Avg. price target upside | +1022.75% | — |
| Average volume | 55.52K | 302.71K |
| Shares outstanding | 1.80M | 10.80M |
| Employees | 1 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed LSTA by 845.9 percentage points over the past year.
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
GTBP vs LSTA FAQ
Which is bigger, GT Biopharma or Lisata Therapeutics?
GT Biopharma (GTBP) is larger, with a market capitalization of $12.05M compared with $11.45M for Lisata Therapeutics (LSTA).
Which stock has performed better over the past year, GTBP or LSTA?
GTBP returned +789.48% over the past 12 months, compared with -56.38% for LSTA (price return, excluding dividends). Past performance does not predict future results.
Are GT Biopharma and Lisata Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.